Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
NEOadjuvant Iparomlimab and Tuvonralimab (QL1706) Plus Chemotherapy in Patients With Hormone Receptor Positive And HER2-Negative Breast Cancer: a Prospective, Single Arm, Multicenter Clinical Trial
RenJi Hospital
55 participants
May 1, 2026
INTERVENTIONAL
Conditions
Summary
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Eligibility
Inclusion Criteria5
- Aged ≥18 years
- Histologically confirmed hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer
- Subjects with at least one evaluable lesion
- ECOG 0-1
- Adequate organ function
Exclusion Criteria2
- Metastatic disease (Stage IV)
- Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
5.0mg/kg qw, start from C1D15
80mg/m\^2 qw
AUC=1.5, D1, 8, 15, every 28 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07396324